Simmitinib - CSPC Pharmaceutical Group
Alternative Names: SYHA-1817Latest Information Update: 28 Apr 2025
At a glance
- Originator CSPC Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Colony-stimulating factor receptor antagonists; Fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Squamous cell cancer
- No development reported Cholangiocarcinoma; Gastric cancer; Solid tumours
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Cholangiocarcinoma in China
- 28 Apr 2025 No recent reports of development identified for phase-I development in Gastric-cancer in China
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO)